Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Rating) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 895,100 shares, an increase of 35.1% from the March 31st total of 662,700 shares. Currently, 4.3% of the company’s stock are sold short. Based on an average daily volume of 383,900 shares, the short-interest ratio is presently 2.3 days.
A number of equities analysts recently issued reports on SBTX shares. Stifel Nicolaus cut Silverback Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $32.00 to $6.00 in a report on Friday, April 1st. Jonestrading lowered Silverback Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, April 1st. The Goldman Sachs Group lowered Silverback Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, April 1st. HC Wainwright lowered Silverback Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, April 1st. Finally, SVB Leerink lowered Silverback Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, April 1st. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Silverback Therapeutics currently has an average rating of “Hold” and an average target price of $27.35.
Shares of Silverback Therapeutics stock opened at $3.11 on Monday. Silverback Therapeutics has a 1 year low of $3.06 and a 1 year high of $35.63. The company’s fifty day simple moving average is $3.63.
Silverback Therapeutics Company Profile (Get Rating)
Silverback Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers.
- Get a free copy of the StockNews.com research report on Silverback Therapeutics (SBTX)
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.